<DOC>
	<DOCNO>NCT02132234</DOCNO>
	<brief_summary>The aim study evaluate influence anti tumor necrosis factor-alpha ( TNF-Î± ) treatment blood pressure , endothelial function immune cell phenotype patient rheumatoid arthritis , psoriatic arthritis ankylose spondylitis .</brief_summary>
	<brief_title>Effects Biological Treatment Blood Pressure Endothelial Function Patients With Rheumatoid Arthritis , Psoriatic Arthritis Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>For patient suffer rheumatoid arthritis : rheumatoid arthritis diagnose base The American Rheumatism Association Criteria 1987 ineffective treatment 2 diseasemodifying antirheumatic drug ( DMARDs ) 6 month , include treatment maximal dos methotrexate least 3 month ( intolerance treatment ) high disease activity Disease Activity Score 28 ( DAS 28 ) &gt; 5,1 measure twice , 1month interval patient mainly low limb affect DAS 28 &gt; 3,7 For patient suffer Ankylosing Spondylitis : Ankylosing Spondylitis diagnose base Modified New York Criteria ineffective treatment 2 nonsteroidal antiinflammatory drug ( administer separately ) maximal recommend maximal tolerate dose 3 month high disease activity Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) &gt; 4 measure twice , 12week interval spinal pain &gt; 4cm 10cm Visual Analogue Scale ( VAS ) measure twice , 12week interval general disease activity assessment &gt; 5 ( 010 scale ) perform 2nd VAS BASDAI assessment For patient suffer Psoriatic Arthritis : Psoriatic arthritis diagnose base Bennett Classification Criteria Psoriatic Arthritis ( CASPAR Criteria ) If peripheral joint affect : active disease assess twice , 4week interval stable treatment , 2 DMARDs treatment least 4 month Criteria active disease ( meet ) : At least 5 66 joint swell assessed twice , 4week interval At least 5 68 joint tender assess twice , 4week interval general disease activity assessment 4 5 Likert scale ( 0 5 scale ) perform patient general disease activity assessment 4 5 Likert scale ( 0 5 scale ) perform physician general disease activity assessment &gt; 5 ( 010 scale ) perform 2nd assessment number tender swollen joint If axial joint affect : Sacroiliac joint affect accord New York Criteria Ankylosing Spondylitis Active severe disease assess twice , 12week interval , stable treatment , ineffective treatment 2 nonsteroidal antiinflammatory drug ( administer separately ) maximal recommend maximal tolerate dose 3 month Criteria active disease ( must present ) : BASDAI &gt; 4 measured twice , 12week interval spinal pain &gt; 4cm 10 cm VAS measure twice , 12week interval general disease activity assessment &gt; 5 ( 010 scale ) Patients take steroid stable dose within one month maximal dose 10mg/day prednisone . nonconsenting patient pregnancy breastfeed allergy drug component cardiac insufficiency ( NYHA III IV ) active infection infection within last 3 month : hepatitis , pneumonia , pyelonephritis opportunistic infection within last 2 month : active infection cytomegalovirus , Pneumocystis carinii joint infection within last 12 month endoprosthesis infection within last 12 month time joint replace exacerbation lung , kidney , liver heart insufficiency treatment demyelinate disease symptom pancytopenia aplastic anemia precancer stage neoplasm within last 5 year include solid tumor neoplasm haematopoietic lymphatic system risk recurrence progression active alcoholic disease chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>